<h4>Background</h4>The efficacy and safety of the administration of recombinant human thrombopoietin (rhTPO) in sepsis patients with thrombocytopenia were still inconclusive.<h4>Objectives</h4>To investigate whether rhTPO is a benefit for sepsis patients with thrombocytopenia.<h4>Methods</h4>PubMed, Cochrane library, Embase, China National Knowledge Infrastructure, and Wanfang Database were electronically searched to the randomized controlled trials (RCTs) from inception to March 4, 2020. The gene discussed is THPO; the disease is Thrombocytopenia.